Bryan Doherty1, Vinod E Nambudiri1, William C Palmer2. 1. Grand Strand Medical Center, Myrtle Beach, SC, 29572, USA. 2. Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. Palmer.william@mayo.edu.
Abstract
PURPOSE OF REVIEW: Cholangiocarcinoma is a rare biliary adenocarcinoma associated with poor outcomes. Cholangiocarcinoma is subdivided into extrahepatic and intrahepatic variants. Intrahepatic cholangiocarcinoma is then further differentiated into (1) peripheral mass-forming tumors and (2) central periductal infiltrating tumors. We aimed to review the currently known risk factors, diagnostic tools, and treatment options, as well as highlight the need for further clinical trials and research to improve overall survival rates. RECENT FINDINGS: Cholangiocarcinoma has seen significant increase in incidence rates over the last several decades. Most patients do not carry the documented risk factors, which include infections and inflammatory conditions, but cholangiocarcinoma typically forms in the setting of cholestasis and chronic inflammation. Management strategies include multispecialty treatments, with consideration of surgical resection, systemic chemotherapy, and targeted radiation therapy. Surgically resectable disease is the only curable treatment option, which may involve liver transplantation in certain selected cases. Referrals to centers of excellence, along with enrollment in novel clinical trials are recommended for patients with unresectable or recurrent disease. This article provides an overview of cholangiocarcinoma and discusses the current diagnosis and treatment options. While incidence is increasing and more risk factors are being discovered, much more work remains to improve outcomes of this ominous disease.
PURPOSE OF REVIEW: Cholangiocarcinoma is a rare biliary adenocarcinoma associated with poor outcomes. Cholangiocarcinoma is subdivided into extrahepatic and intrahepatic variants. Intrahepatic cholangiocarcinoma is then further differentiated into (1) peripheral mass-forming tumors and (2) central periductal infiltrating tumors. We aimed to review the currently known risk factors, diagnostic tools, and treatment options, as well as highlight the need for further clinical trials and research to improve overall survival rates. RECENT FINDINGS:Cholangiocarcinoma has seen significant increase in incidence rates over the last several decades. Most patients do not carry the documented risk factors, which include infections and inflammatory conditions, but cholangiocarcinoma typically forms in the setting of cholestasis and chronic inflammation. Management strategies include multispecialty treatments, with consideration of surgical resection, systemic chemotherapy, and targeted radiation therapy. Surgically resectable disease is the only curable treatment option, which may involve liver transplantation in certain selected cases. Referrals to centers of excellence, along with enrollment in novel clinical trials are recommended for patients with unresectable or recurrent disease. This article provides an overview of cholangiocarcinoma and discusses the current diagnosis and treatment options. While incidence is increasing and more risk factors are being discovered, much more work remains to improve outcomes of this ominous disease.
Entities:
Keywords:
Biliary adenocarcinoma; Biliary tract cancer; Cholangiocarcinoma; Diagnosis and treatment; Gall bladder; Rare hepatic tumor
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Emmanuel E Zervos; Dana Osborne; Steven B Goldin; Desiree V Villadolid; Donald P Thometz; Alan Durkin; Larry C Carey; Alexander S Rosemurgy Journal: Am J Surg Date: 2005-11 Impact factor: 2.565
Authors: A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron Journal: Ann Surg Date: 1996-10 Impact factor: 12.969
Authors: Samuel C Fehling; Aubrey L Miller; Patrick L Garcia; Rebecca B Vance; Karina J Yoon Journal: Cancer Lett Date: 2019-10-09 Impact factor: 8.679
Authors: Rachel M Lee; Yuan Liu; Adriana C Gamboa; Mohammad Y Zaidi; David A Kooby; Mihir M Shah; Kenneth Cardona; Maria C Russell; Shishir K Maithel Journal: J Surg Oncol Date: 2019-07-13 Impact factor: 3.454
Authors: Steffen Marquardt; Martha M Kirstein; Roland Brüning; Martin Zeile; Pier Francesco Ferrucci; Warner Prevoo; Boris Radeleff; Hervé Trillaud; Lambros Tselikas; Emilio Vicente; Philipp Wiggermann; Michael P Manns; Arndt Vogel; Frank K Wacker Journal: Eur Radiol Date: 2018-09-25 Impact factor: 5.315